SLC5A2 and type 2 diabetes mellitus: Empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, improves glycemic control in patients with T2DM when used as monotherapy or in combination with other oral hypoglycemic agents (OHA), and weight loss is also a consistent feature associated with this medication [8,9].